Seoul National University; The additive effects of TRAIL and p53 gene therapy diminish cancer cell growth
Posted on: Thursday, 12 February 2004, 06:00 CST
2004 FEB 18 - (NewsRx.com & NewsRx.net) -- The additive effects of TRAIL and p53 gene therapy diminish cancer cell growth.
"Tumor necrosis factor-alpha-related apoptosis-inducing ligand (TRAIL) is a cytokine that can induce tumor-specific apoptosis through its specific death receptors (DR4 and DR5) and p53 has been proven to increase the expression of death receptors. To examine their interaction in tumor suppression, p53 and TRAIL genes were inserted in recombinant adenovirus vectors and transferred simultaneously into non-small cell lung cancer cell lines (NCI- H157, NCI-H358, NCI-H460 and A549). Western blot assay demonstrated production of TRAIL protein in NCI-H157 and A549 cell lines," scientists writing in the International Journal of Molecular Medicine report.
"Increased expressions of DR4 and DR5 of NCI-H157 and DR4 of A549 after p53 overexpression were confirmed by flow cytometry. p53 or TRAIL gene transfer increased sub-G1 fraction in cell cycle analysis and inhibited the tumor growth dose-dependently and the degree was potentiated by co-transfer. But isobologram analysis indicated an additive effect," said S.H. Jang and colleagues, Seoul National University, Bundang Hospital.
"Together, these data indicate that p53 and TRAIL interact additively on tumor apoptosis despite theoretical synergism," investigators concluded.
Jang and colleagues published their study in International Journal of Molecular Medicine (Additive effect of TRAIL and p53 gene transfer on apoptosis of human lung cancer cell lines. Int J Mol Med, 2004;13(1):181-186).
Additional information can be obtained by contacting C.T. Lee, Seoul National University, Bundang Hospital, Department Internal Medicine, 300 Gumidong, Gyeonggi Do 463707, South Korea.
The publisher of the International Journal of Molecular Medicine can be contacted at: Professor D.A. Spandidos, 1, S Merkouri St., Editorial Office, Athens 116 35, Greece.
The information in this article comes under the major subject areas of Cancer Suppression, Gene Therapy, Oncology and Lung Cancer.
This article was prepared by Biotech Week editors from staff and other reports. Copyright 2004, Biotech Week via NewsRx.com & NewsRx.net.
Related Articles
- Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy
- Data From Studies of Amrubicin in Small-Cell Lung Cancer Presented at the 2008 American Society of Clinical Oncology Meeting Demonstrate Single Agent Anti-Tumor Activity in Western Patient Population
- Amrubicin is Designated As an Orphan Medicinal Product By the European Commission for the Treatment of Small Cell Lung Cancer
- Introgen's P53 Immunotherapy Drug Candidate to Advance Into Second Phase 2 Clinical Trial in Small Cell Lung Cancer With National Cancer Institute
- An Overview of Testicular Germ Cell Tumors
- Study Reinforces Potential Utility of ONCONASE(R) in Non-Small-Cell Lung Cancer
- Talabostat Phase 2 Non-Small Cell Lung Cancer Trial Featured at the 14th International Conference on Gene Therapy of Cancer
- Pivotal Phase III Tarceva Study Published in the New England Journal of Medicine Showed Survival Improvement in Advanced Non-Small Cell Lung Cancer
- Biological Variation of Tumor Markers and Its Application in the Detection of Disease Progression in Patients With Non-Small Cell Lung Cancer
- Point Therapeutics Achieves Interim Tumor Response Criteria in Phase 2 Non-Small Cell Lung Cancer Study; Company Advances Talabostat to Second Stage of Study
 |
 |
User Comments (0)
RSS Feeds